Drugs / PF-05105679
PF-05105679
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05935280 | Jul → Sep 2023 | — | Medical University of Vienna | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01393652 Comparator | May → Sep 2011 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-05105679 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05935280 ↗ |
| Known as | (R)-3-[(1-(4-fluorophenyl)ethyl)(quinolin-3-ylcarbonyl)amino]methylbenzoic acid | “We have identified a moderately potent (IC50 = 103 nM), selective TRPM8 antagonist, PF-05105679 [(R)-3-[(1-(4-fluorophenyl)ethyl)(quinolin-3-ylcarbonyl)amino]methylbenzoic acid].” PMID 25125580 ↗ Aug 2014 |
| Known as | PF 5105679 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3577885 ↗ |
| Action | Inhibit | “Specific antagonist of the TRPM8 ion channel” NCT05935280 ↗ |
| Modality | Small molecule | — CHEMBL3577885 ↗ |
| Route | Other | “Pain induced by intradermal injection of increasingly cold fluid down to 3°C including PF-05105679 (specific TRPM8 antagonist).” NCT05935280 ↗ |